Compare companies
Put any US companies we track side by side — SEC-sourced financials, ratios, forensic scores, and our Quality Score. Add up to four. No market price, no paywall.
ImmunityBio, Inc.
| Metric | ImmunityBio, Inc. IBRXHealthcare |
|---|---|
| Quality Score | 56 / 100 |
| Revenue (latest) | $113M |
| Net income (latest) | −$351M |
| Operating margin | −226.0% |
| Net margin | −310.2% |
| Return on equity | 70.2% |
| Return on assets | −70.0% |
| Return on capital (ROCE) | −58.2% |
| Debt / equity | — |
| Revenue growth (YoY) | 668.3% |
| Altman Z″ (distress) | -24.85 |
| Accruals / assets | −9.3% |
Latest reported figures from each company's own SEC filings (XBRL) plus our derived scores. Blank where a line item isn't cleanly tagged — never estimated. Descriptive factors, not advice. Open a company for its full multi-year history.